ALNY

Alnylam Pharmaceuticals, Inc. (ALNY)

Last Price$246.3(1.2%)
Market Cap$31.7B

ALNY Rating

Crunching data... Almost there!

ALNY Intrinsic Value

Instantly access our exclusive intrinsic value analysis.
Get Access for FREE

ALNY Share Price History

1W 3.5%
1M (0.1%)
6M 2.6%
YTD 26.3%
1Y 30.6%
3Y 76.9%
5Y 107.3%
10Y 155.9%
Share Price
Drawdown
Total Return
vs SP500
vs NASDAQ
$160.0$180.0$200.0$220.0$240.0$260.0$280.0$300.0Feb'24Mar'24Apr'24May'24Jun'24Jul'24Aug'24Sep'24Oct'24Nov'24Dec'24Jan'25
Value Sense

ALNY Stock Metrics

Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Access full financial data and insights for free.
Sign Up Now

ALNY Stock Financials

ALNY Income Statement Metrics

Crunching data... Almost there!

ALNY Cash Flow Statement Metrics

Crunching data... Almost there!

ALNY Income Statement Overview

Crunching data... Almost there!

ALNY Balance Sheet Overview

Crunching data... Almost there!

ALNY Stock Ratios

Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
Crunching data... Almost there!
Crunching data... Almost there!
Crunching data... Almost there!
Crunching data... Almost there!
Crunching data... Almost there!
Crunching data... Almost there!
Crunching data... Almost there!
Crunching data... Almost there!

ALNY Earnings Surprises

Crunching data... Almost there!

ALNY Dividends

ALNY Dividend Yield

Crunching data... Almost there!

ALNY Dividend Per Share

Crunching data... Almost there!

Competing with ALNY

Overview
Ratings
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Crunching data... Almost there!

FAQ

What is Alnylam Pharmaceuticals, Inc. (ALNY) stock rating?

As of today, Alnylam Pharmaceuticals, Inc. has a stock rating of 6 (out of 10), which is considered Good.

is Alnylam Pharmaceuticals, Inc. (ALNY) a good stock to buy?

As of today, Alnylam Pharmaceuticals, Inc. has a Good stock rating, which is 62.9% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.